382 related articles for article (PubMed ID: 37091970)
1. Modulation of T-cell function by myeloid-derived suppressor cells in hematological malignancies.
Bhardwaj V; Ansell SM
Front Cell Dev Biol; 2023; 11():1129343. PubMed ID: 37091970
[TBL] [Abstract][Full Text] [Related]
2. Myeloid-derived suppressor cells: key immunosuppressive regulators and therapeutic targets in hematological malignancies.
Wang S; Zhao X; Wu S; Cui D; Xu Z
Biomark Res; 2023 Mar; 11(1):34. PubMed ID: 36978204
[TBL] [Abstract][Full Text] [Related]
3. The New Era of Cancer Immunotherapy: Targeting Myeloid-Derived Suppressor Cells to Overcome Immune Evasion.
De Cicco P; Ercolano G; Ianaro A
Front Immunol; 2020; 11():1680. PubMed ID: 32849585
[TBL] [Abstract][Full Text] [Related]
4. Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression.
Groth C; Hu X; Weber R; Fleming V; Altevogt P; Utikal J; Umansky V
Br J Cancer; 2019 Jan; 120(1):16-25. PubMed ID: 30413826
[TBL] [Abstract][Full Text] [Related]
5. Myeloid-Derived Suppressor Cells in the Tumor Microenvironment.
Dysthe M; Parihar R
Adv Exp Med Biol; 2020; 1224():117-140. PubMed ID: 32036608
[TBL] [Abstract][Full Text] [Related]
6. Myeloid-derived suppressor cells in B cell malignancies.
Yazdani Y; Mohammadnia-Afrouzi M; Yousefi M; Anvari E; Ghalamfarsa G; Hasannia H; Sadreddini S; Jadidi-Niaragh F
Tumour Biol; 2015 Sep; 36(10):7339-53. PubMed ID: 26330296
[TBL] [Abstract][Full Text] [Related]
7. Targeting Myeloid-Derived Suppressor Cells to Enhance the Antitumor Efficacy of Immune Checkpoint Blockade Therapy.
Li X; Zhong J; Deng X; Guo X; Lu Y; Lin J; Huang X; Wang C
Front Immunol; 2021; 12():754196. PubMed ID: 35003065
[TBL] [Abstract][Full Text] [Related]
8. Targeting myeloid-derived suppressor cells in tumor immunotherapy: Current, future and beyond.
Zhao Y; Du J; Shen X
Front Immunol; 2023; 14():1157537. PubMed ID: 37006306
[TBL] [Abstract][Full Text] [Related]
9. Myeloid-Derived Suppressor Cells in
Fresno M; Gironès N
Front Cell Infect Microbiol; 2021; 11():737364. PubMed ID: 34513737
[TBL] [Abstract][Full Text] [Related]
10. Targeting Myeloid-Derived Suppressor Cell, a Promising Strategy to Overcome Resistance to Immune Checkpoint Inhibitors.
Hou A; Hou K; Huang Q; Lei Y; Chen W
Front Immunol; 2020; 11():783. PubMed ID: 32508809
[TBL] [Abstract][Full Text] [Related]
11. Targeting Myeloid-Derived Suppressor Cells in Cancer Immunotherapy.
Wang Y; Jia A; Bi Y; Wang Y; Yang Q; Cao Y; Li Y; Liu G
Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32942545
[TBL] [Abstract][Full Text] [Related]
12. Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression.
Fleming V; Hu X; Weber R; Nagibin V; Groth C; Altevogt P; Utikal J; Umansky V
Front Immunol; 2018; 9():398. PubMed ID: 29552012
[TBL] [Abstract][Full Text] [Related]
13. Myeloid-derived suppressor cells as therapeutic target in hematological malignancies.
De Veirman K; Van Valckenborgh E; Lahmar Q; Geeraerts X; De Bruyne E; Menu E; Van Riet I; Vanderkerken K; Van Ginderachter JA
Front Oncol; 2014; 4():349. PubMed ID: 25538893
[TBL] [Abstract][Full Text] [Related]
14. The prognostic value and therapeutic targeting of myeloid-derived suppressor cells in hematological cancers.
Fan R; De Beule N; Maes A; De Bruyne E; Menu E; Vanderkerken K; Maes K; Breckpot K; De Veirman K
Front Immunol; 2022; 13():1016059. PubMed ID: 36304465
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy of targeting MDSCs in tumor microenvironment.
Sui H; Dongye S; Liu X; Xu X; Wang L; Jin CQ; Yao M; Gong Z; Jiang D; Zhang K; Liu Y; Liu H; Jiang G; Su Y
Front Immunol; 2022; 13():990463. PubMed ID: 36131911
[TBL] [Abstract][Full Text] [Related]
16. Evolution and Targeting of Myeloid Suppressor Cells in Cancer: A Translational Perspective.
Bleve A; Consonni FM; Porta C; Garlatti V; Sica A
Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35158779
[TBL] [Abstract][Full Text] [Related]
17. ILT3 (LILRB4) Promotes the Immunosuppressive Function of Tumor-Educated Human Monocytic Myeloid-Derived Suppressor Cells.
Singh L; Muise ES; Bhattacharya A; Grein J; Javaid S; Stivers P; Zhang J; Qu Y; Joyce-Shaikh B; Loboda A; Zhang C; Meehl M; Chiang DY; Ranganath SH; Rosenzweig M; Brandish PE
Mol Cancer Res; 2021 Apr; 19(4):702-716. PubMed ID: 33372059
[TBL] [Abstract][Full Text] [Related]
18. Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy.
Wu Y; Yi M; Niu M; Mei Q; Wu K
Mol Cancer; 2022 Sep; 21(1):184. PubMed ID: 36163047
[TBL] [Abstract][Full Text] [Related]
19. Myeloid-Derived Suppressor Cells and Mesenchymal Stem/Stromal Cells in Myeloid Malignancies.
Kapor S; Santibanez JF
J Clin Med; 2021 Jun; 10(13):. PubMed ID: 34202907
[TBL] [Abstract][Full Text] [Related]
20. Myeloid-Derived Suppressor Cells: Ductile Targets in Disease.
Consonni FM; Porta C; Marino A; Pandolfo C; Mola S; Bleve A; Sica A
Front Immunol; 2019; 10():949. PubMed ID: 31130949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
